Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples